Youth. Charm. Fearlessness. Ruthless focus. These can be positive attributes in an entrepreneur, but in a more rational world, technology investors wouldn’t overvalue them. Risk capital would be allocated based mostly on evidence, data, progress towards milestones—in short, on proof.
In... Read more »
Editing human DNA has entered the public consciousness in a big way in recent years with its increasing use in laboratories—and, in recent news that shocked the scientific community, in embryos—of tools such as CRISPR-Cas9.
Locana, a gene therapy... Read more »
It’s been a year since Ford announced it will refurbish a massive abandoned train station in Detroit and transform it into the anchor of its mobility and autonomous vehicle operations, which will eventually house hundreds of employees.
This week, the automaker... Read more »
Cancer remains one of the hottest areas for pharma deals and this week saw a big one: Pfizer’s proposed $11.4 billion buyout of Array Biopharma.
The announcement comes less than a month after Boulder, CO-based Array announced positive data from a... Read more »
[Updated 8:50 am, 6/21/19. See below.] Two weeks-worth of Boston tech news coming your way that covers new cash, executive moves, wary public sentiment on facial recognition, a mega-merger, and more.
—Venture capital firm Polaris Partners is looking to raise $400... Read more »
It’s been a strong year for biotech IPOs and Wednesday shaped up to be a particularly busy day as four life science firms debuted on the public markets.
So far this year, 72 companies have gone public, according to IPO research... Read more »
Boston—The 2019 Xconomy Awards are designed to celebrate the accomplishments and promise of Boston’s life sciences community, and we are excited to announce the emcees for this year’s gala.
Michael Gilman, CEO of Arrakis Therapeutics, and Katrine Bosley, who formerly... Read more »
Life has been changing at Veracode so rapidly in the past two years that you could easily forgive someone for not remembering who owned the company on any given day.
Focused on cybersecurity for application development, Burlington, MA-based Veracode had raised... Read more »
There’s a speed dating game of sorts happening as pharmaceutical companies that have approved cancer immunotherapies are testing their medications in combination with experimental drugs in hopes of reaching more patients.
San Diego’s Oncolytics Biotech (NASDAQ: ONCY) has been an... Read more »
Most of the genetic analysis done today is performed on machines made by Illumina, the DNA sequencing giant.
Now a former director from the company is leading a startup that has raised $15 million to develop new genome sequencing tools.
San... Read more »
It’s time to catch up on some recent Wisconsin innovation news:
—Green Bay Packers quarterback Aaron Rodgers has a new title: venture capitalist. He co-founded and serves as general partner of Rx3 Ventures, a Newport Beach, CA-based firm that recently... Read more »
Gilead Sciences is turning to Nurix Therapeutics in an effort to discover new drugs that harness the cellular machinery our bodies use to dispose of damaged or harmful proteins.
Foster City, CA-based Gilead (NASDAQ: GILD) will pay Nurix $45 million... Read more »
Those of us who like to ride our bikes on city streets know the importance of The Staredown. Say a biker is trundling past an intersection and a car is inching forward to make a righthand turn while the light is... Read more »